Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study - Concepedia

Concepedia

Publication | Open Access

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

DOI Full Paper Access

23

Citations

8

References

2017

Year

Marina Elena Cazzaniga, Mario Airoldi, Valentina Arcangeli, Salvatore Artale, Francesco Atzori, A Ballerio, Giulia Bianchi, Livio Blasi, Serena Campidoglio, Mariangela Ciccarese,

Abstract

The EVA study provided new insights in the use of EVE-EVE combination in HR+ ABC pts many years after the publication of the pivotal trial. The combination is safe and the best response could be obtained in patients receiving the full dose of EVE and/or after hormone-therapy as Fulvestrant in ABC.

References

	Year	Citations

Page 1